SCHEMBL15723976

SCHEMBL15723976

CC(C)c1nccnc1-c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 3/20 0.44
CDK1 P06493 3/20 0.44
CCNB1 P14635 3/20 0.44
CCNB3 Q8WWL7 3/20 0.44
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM5B Q9UGL1 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
MAPK14 Q16539 1/20 0.37
AKT1 P31749 2/20 0.37
GCGR P47871 2/20 0.36
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15724386 0.82 SYK (0.37) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL30009700 0.81 MAPK14 (0.43) KDM5BPDE3BPDE3AMAPK14GCGR
SCHEMBL12277718 0.81 MAPK14 (0.43) KDM5BPDE3BPDE3AMAPK14GCGR
SCHEMBL12141867 0.80 KDM4E (0.42) CDK5CDK5R1KDM5BPDE3BPDE3A
SCHEMBL11681904 0.80 MAOA (0.41) CYP1A2CYP2C9CYP2C19PDE3BPDE3A
SCHEMBL4691850 0.79 PDE3B (0.47) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL11676720 0.79 ALDH1A1 (0.39) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL14525876 0.77 IDO1 (0.49) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL24926786 0.77 TGFBR1 (0.33) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL12277748 0.77 KIF11 (0.46) CCNB2CDK1CCNB1CCNB3GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN CCNB2 3384/4885CDK1 1913/4885CCNB1 2503/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN CCNB2 3384/4885CDK1 1913/4885CCNB1 2503/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN CCNB2 3384/4885CDK1 1913/4885CCNB1 2503/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN CCNB2 3384/4885CDK1 1913/4885CCNB1 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.